| Previous Close | 0.1848 |
| Open | 0.1895 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1800 - 0.2222 |
| 52 Week Range | 0.1000 - 0.6400 |
| Volume | 105,994 |
| Avg. Volume | 163,549 |
| Market Cap | 34.465M |
| Beta (3Y Monthly) | -2.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0870 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Product revenue for the third quarter of 2018 was approximately $260,000, up 67% from the third quarter of 2017. Product revenue for the nine month period was up 99% from the nine month period in 2017.
SUWANEE, GA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) announced today that the Company will release financial results for the third quarter ended September 30, 2018 this week. The Company will also host a conference call on Thursday, November 15, 2018, beginning at 10AM Eastern Time to discuss the third quarter financial results, provide a business update and answer questions. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.
SUWANEE, GA, Oct. 31, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave will exhibit at.
SUWANEE, GA , Oct. 17, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company will exhibit at SAWC (Symposium on Advanced.
SUWANEE, GA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave, Inc. and the dermaPACE® device were featured on American Indian Living Radio during the September 24, 2018 broadcast hosted by Dr. David DeRose. Dr. DeRose began the interview by saying that he had never heard of using shock waves to treat diabetic foot ulcers (DFUs) but had looked at some of the scientific photographs and found them to be “pretty impressive stuff.” Stolarski replied that the treatment was “very legitimate” and noted that the device was recently cleared by the FDA on December 28, 2017. Stolarski continued by detailing the 336-patient double-blinded, randomly-controlled FDA study conducted without physician assisted closure and without the assistance of antimicrobial or antibacterial assistance which achieved statistically significant rates of complete closure by 20 weeks in DFUs treated with dermaPACE® in conjunction with standard of care as compared to wounds treated with only standard of care.
SUWANEE, GA, Sept. 06, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave, Inc. will exhibit the dermaPACE® device at the 35th Annual National Tribal Health Conference at the Oklahoma City Cox Convention Center in Oklahoma City, OK, September 17 - 20, 2018. The National Tribal Health Conference is the largest American Indian and Alaska Native specific gathering focused on health every year.
Q2 Results, Operational Update: International Expansion Continues With 2 New JVs Signed in Q2…. Revenue continues to gain momentum, reflecting initial contribution from the recent U.S. launch and, to a greater degree, SNWV’s ever-expanding international footprint. Q2 revenue of $453k, which is the second-highest quarterly revenue in company history, was up more than 300% from the prior year and 32% from Q1 ’18.
PHOENIX, Aug. 21, 2018 (GLOBE NEWSWIRE) -- (SNWV) -- SANUWAVE Health, Inc.’s Chairman and CEO, Kevin Richardson, Returns to Uptick Newswire’s “Stock Day” Podcast to report on a 300% increase in revenue. Richardson responded that the Company had its best 2nd Quarter ever. The sales in the 2nd Quarter were driven by international deals that really came to light because of the FDA approval.
Q1 ’18 marked a milestone for SNWV - or more accurately, marked three milestones. The $344k of revenue is the highest Q1 revenue in company history and it included U.S. dermaPACE revenue – which is another first. U.S. dermaPACE revenue relates to the first shipments to Premier Shockwave.